Therapeutic effects of ulinastatin on postoperative complications and cognitive function in elderly patients with esophageal cancer after thoracic laparoscopic surgery

Abstract


 
 
 
 Purpose: To investigate the therapeutic effect of ulinastatin on postoperative complications and cognitive function in elderly patients with esophageal cancer after thoracic laparoscopic surgery.
 Methods: A total of 100 elderly in-patients with esophageal cancer who had undergone thoracic laparoscopic surgery from April 2019 to December 2020 were selected and randomly assigned to control and study groups. Patients in control group received conventional treatment, while those in the study group were administered ulinastatin. The two groups were compared with respect to response, incidence of postoperative complications, Mini-Mental State Examination (MMSE) cognitive function score, Barthel Index (BI) scores; preoperative, intraoperative, 12-h and 24-h post-surgery levels of IL-1β and IL-6; levels of CD3+, CD4+ and CD8+, as well as duration of surgery and waking time.
 Results: Response, MMSE score, BI index, and levels of CD3+, CD4+ and CD8+ in the study group were significantly higher than those in the control group (p < 0.05). Incidence of postoperative complications, and expression levels of IL-1β and IL-6 12 h and 24 h after surgery in the study group were lower than the corresponding control levels (p < 0.05). There were no significant differences in duration of operation and waking time between the two groups (p > 0.05).
 Conclusion: Ulinastatin significantly reduces postoperative complications, and also improves cognitive function in elderly patients with esophageal cancer after thoracic laparoscopic surgery. This finding is of great significance in the treatment of these patients.
 
 
 

Clinical significance of peroxiredoxin 2 in esophageal squamous cell carcinoma and its role in cell proliferation and apoptosis <i>in vitro,/i>

“…CF = (NC/ICN)100 ………………. (2) where CF is the Clone formation rate, and ICN is the inoculated cell number…”

“…Esophageal carcinoma (EC) is a common malignant tumor of the digestive tract. Statistics have revealed that more than 300,000 people die from EC every year globally [1,2] and its 5-year survival rate was reported to range from 10 -40 % [3,4]. Esophageal squamous cell carcinoma (ESCC) is the main pathological type of EC [5].…”